Harnessing Terbium-161 for FAP-Targeted Theranostics: Radiolabeling and In Vitro Characterization of [¹⁶¹Tb]Tb-FAPI-46 and [¹⁶¹Tb] Tb-FAP-2286 (EANM 2026) - Sep 29, 2026 - Abstract #EP-1285; "Using the optimized protocol, [¹⁶¹Tb]Tb-FAPI-46 and [¹⁶¹Tb] Tb-FAP-2286 were successfully radiolabeled with high radiochemical yield, with [¹⁶¹Tb]Tb-FAPI-46 exhibiting superior stability. These findings support the potential of both compounds as promising candidates for FAP-targeted theranostic applications and warrant further evaluation in subsequent in vivo studies. Importantly, this work represents the initial step of a broader study designed to comparatively evaluate these agents in a tumor-specific therapeutic context, with subsequent in vivo investigations planned."
Preclinical
|
|
C. Sezgin 1; E. Uygur 2; D. Baran 3; R. Çelik 3; B. Özel 2; Y. Parlak 2; F. Gümüşer 4; F. Biber Müftüler 3
|